AtriCure Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
11,462.00
16,211.00
27,212.00
33,338.00
26,892.00
21,137
Depreciation, Depletion & Amortization
2,020.00
4,774.00
6,278.00
9,299.00
9,128.00
8,754
Other Funds
26,872.00
-
10,892.00
-
-
6,813
Funds from Operations
5,988.00
10,562.00
10,445.00
10,040.00
6,942.00
5,570
Changes in Working Capital
766.00
11,038.00
2,603.00
5,079.00
2,002.00
1,399
Net Operating Cash Flow
5,222.00
21,600.00
7,842.00
15,119.00
8,944.00
4,171
Capital Expenditures
2,864.00
9,207.00
13,445.00
7,692.00
6,384.00
Sale of Fixed Assets & Businesses
3,756.00
77.00
-
3.00
-
Purchase/Sale of Investments
15,043.00
21,493.00
21,077.00
4,390.00
10,145.00
Net Investing Cash Flow
14,151.00
30,623.00
10,501.00
12,079.00
3,761.00
Issuance/Reduction of Debt, Net
2,154.00
2,864.00
263.00
24,441.00
1,739.00
Net Financing Cash Flow
26,828.00
65,871.00
13,961.00
27,695.00
2,760.00
Net Change in Cash
7,139.00
13,492.00
4,620.00
444.00
2,399.00
Free Cash Flow
8,086.00
30,807.00
21,287.00
22,811.00
15,328.00
Net Assets from Acquisitions
-
-
7,581.00
-
-
Change in Capital Stock
2,110.00
68,735.00
3,394.00
3,254.00
4,499.00
Exchange Rate Effect
316.00
156.00
238.00
53.00
24.00
Other Uses
-
-
10,552.00
-
-

About AtriCure

View Profile
Address
7555 Innovation Way
Mason Ohio 45069
United States
Employees -
Website http://www.atricure.com
Updated 07/08/2019
AtriCure, Inc. engages provision of treatment of atrial fibrillation and left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International. Its product, Isolator Synergy Ablation System, is a surgical device that treats the persistent longstanding persistent forms of atrial fibrillation in patients undergoing certain open concomitant procedures.